RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mannose-binding lectin 2 secreted by hepatocellular carcinoma cells recruits and activates natural killer cells to reshape an immune-activated microenvironment.
Mannose-binding lectin 2 secreted by hepatocellular carcinoma cells recruits and activates natural killer cells to reshape an immune-activated microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肝细胞癌(HCC)与肿瘤微环境(TME)之间的交互作用对HCC的发生和治疗至关重要。自然杀伤(NK)细胞在TME中的浸润和功能经常受到阻碍。
然而,尚不清楚来自HCC细胞的关键调控因子是否直接调节NK细胞活性以逃避免疫监视。在本研究中,我们发现甘露糖结合凝集素2(MBL2)在HCC中表达显著降低,并与HCC预后呈正相关。MBL2在细胞内抑制HCC细胞的增殖和迁移。建立HCC与NK细胞的人和小鼠共培养体系,证明分泌型MBL2在TME中招募并激活NK细胞,特别是上调NKp46+ NK细胞的浸润。
此外,分泌型MBL2促进NK细胞产生IL-13和IL-25,导致耗竭的细胞毒性T淋巴细胞减少。在机制上,MBL2与整合素β1受体相互作用,激活FAK/AKT通路并增加NK细胞上PD-L1的表达。
我们的发现确定了MBL2是一种NK细胞激活细胞因子,在NK细胞中启动整合素β1/FAK/AKT通路,并重塑HCC的免疫激活微环境。上调MBL2的策略可能增强抗PD-L1免疫治疗的疗效,并作为HCC的潜在治疗手段。
Crosstalk between hepatocellular carcinoma (HCC) and the tumor microenvironment (TME) is pivotal for the initiation and management of HCC. The infiltration and function of natural killer (NK) cells in the TME are frequently hindered.
However, it is unclear whether a crucial regulatory factor originating from HCC cells directly modulates NK cell activity to evade immune surveillance. In this study, we found that mannose-binding lectin 2 (MBL2) expression was markedly decreased in HCC and positively correlated with HCC prognosis.
MBL2 inhibited the proliferation and migration of HCC cells intracellularly. Human and murine co-culture systems of HCC and NK cells were established to demonstrate that secreted MBL2 recruited and activated NK cells in the TME, particularly upregulating the infiltration of NKp46+ NK cells.
Furthermore, secreted MBL2 promoted the production of IL-13 and IL-25 by NK cells, resulting in a decrease in exhausted cytotoxic T lymphocytes.
Mechanistically, MBL2 interacts with the integrin β1 receptor, activating the FAK/AKT pathway and increasing PD-L1 expression on NK cells.
Our discovery identifies MBL2 as an NK cell-activating cytokine, initiating the integrin β1/FAK/AKT pathway in NK cells and reshaping an immune-activated microenvironment of HCC. Strategies to up-regulate MBL2 may enhance the anti-PD-L1 immunotherapy efficacy and serve as a potential therapeutic approach for HCC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。